Ciclosporin controlled release - Midatech

Drug Profile

Ciclosporin controlled release - Midatech

Alternative Names: Ciclosporin sustained release - Midatech; Cyclosporine sustained release - Midatech; MTD-202; OpsiSporin; Q-Cyclosporin

Latest Information Update: 21 May 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator OpsiRX Pharmaceuticals
  • Developer Midatech
  • Class Antineoplastics; Antipsoriatics; Antirheumatics; Ciclosporins; Eye disorder therapies; Neuroprotectants
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Uveitis

Most Recent Events

  • 21 May 2015 Ciclosporin controlled release is available for licensing as of 21 May 2015.
  • 01 Jan 2015 Preclinical trials in Uveitis in United Kingdom (Intravitreous)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top